非神經(jīng)元性烯醇化酶(ENO1)多克隆抗體
Polyclonal Antibody to Enolase 1 (ENO1)
NNE; ENO1L1; MPB1; PPH; Alpha Enolase; Enolase 1; Phosphopyruvate hydratase; Plasminogen-binding protein; 2-phospho-D-glycerate hydro-lyase; C-myc promoter-binding
- 編號PAB449Hu01
- 物種Homo sapiens (Human,人)相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原RPB449Hu01-非神經(jīng)元性烯醇化酶(ENO1)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度0.5mg/mL
- 且適物種Mus musculus (Mouse,小鼠), Rattus norvegicus (Rat,大鼠)
- 應(yīng)用WB
如果抗體需用于流式細(xì)胞術(shù),請參見流式抗體。 - 下載英文說明書 中文說明書
- 規(guī)格20μl100μl200μl1ml10ml
- 價格¥ 598 ¥ 1394¥ 1992¥ 4980¥ 19920
- 欲了解實際交易價格和更多情況,請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對ENO1的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別ENO1。
用法
Western blotting: 0.01-2μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Analytical Chemistry | Diagnostic detection of human lung cancer-associated antigen using a gold nanoparticle-based electrochemical immunosensor[PubMed: 20557064] |
Translational Research | Proteomic analysis of fine-needle aspiration in differential diagnosis of thyroid nodules[Pubmed:27172385] |
Journal of?Proteomics | Putative salivary biomarkers useful to differentiate patients with fibromyalgia[Pubmed:29654921] |
BioMed Research International | The Diagnostic Accuracy of Combined Enolase/Cr, CA125, and CA19-9 in the Detection of Endometriosis[Pubmed: 33062681] |
Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins[] |
Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression[34376212] |
Clin Proteomics | Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma[Pubmed:35610567] |